JP3826400B2 - ラクタム化合物及びその医薬用途 - Google Patents

ラクタム化合物及びその医薬用途 Download PDF

Info

Publication number
JP3826400B2
JP3826400B2 JP2002546550A JP2002546550A JP3826400B2 JP 3826400 B2 JP3826400 B2 JP 3826400B2 JP 2002546550 A JP2002546550 A JP 2002546550A JP 2002546550 A JP2002546550 A JP 2002546550A JP 3826400 B2 JP3826400 B2 JP 3826400B2
Authority
JP
Japan
Prior art keywords
group
substituent
lactam compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002546550A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2002044180A1 (ja
Inventor
幸生 飯野
孝雄 池上
信雄 近藤
裕之 松枝
敏宏 畑中
竜介 平間
陽子 増澤
史生 太田
晶代 山▲崎▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of JPWO2002044180A1 publication Critical patent/JPWO2002044180A1/ja
Application granted granted Critical
Publication of JP3826400B2 publication Critical patent/JP3826400B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
JP2002546550A 2000-12-01 2001-11-29 ラクタム化合物及びその医薬用途 Expired - Lifetime JP3826400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006134026A Division JP4505753B2 (ja) 2000-12-01 2006-05-12 ラクタム化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
JPWO2002044180A1 JPWO2002044180A1 (ja) 2004-04-02
JP3826400B2 true JP3826400B2 (ja) 2006-09-27

Family

ID=18837660

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002546550A Expired - Lifetime JP3826400B2 (ja) 2000-12-01 2001-11-29 ラクタム化合物及びその医薬用途
JP2006134026A Expired - Fee Related JP4505753B2 (ja) 2000-12-01 2006-05-12 ラクタム化合物及びその医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006134026A Expired - Fee Related JP4505753B2 (ja) 2000-12-01 2006-05-12 ラクタム化合物及びその医薬用途

Country Status (26)

Country Link
US (3) US7153850B2 (https=)
EP (1) EP1346993B1 (https=)
JP (2) JP3826400B2 (https=)
KR (1) KR100826818B1 (https=)
CN (2) CN100577651C (https=)
AT (1) ATE446297T1 (https=)
AU (3) AU1850202A (https=)
BG (1) BG107857A (https=)
BR (1) BR0115852A (https=)
CA (1) CA2430124C (https=)
CZ (1) CZ20031520A3 (https=)
DE (1) DE60140270D1 (https=)
ES (1) ES2331299T3 (https=)
HU (1) HUP0400806A3 (https=)
IL (1) IL156158A0 (https=)
MX (1) MXPA03004876A (https=)
NO (1) NO325401B1 (https=)
NZ (1) NZ526164A (https=)
PL (1) PL362835A1 (https=)
RU (1) RU2287530C2 (https=)
SK (1) SK6582003A3 (https=)
TW (1) TWI241302B (https=)
UA (1) UA76969C2 (https=)
WO (1) WO2002044180A1 (https=)
YU (1) YU42603A (https=)
ZA (1) ZA200304100B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213732A (ja) * 2000-12-01 2006-08-17 Ajinomoto Co Inc ラクタム化合物及びその医薬用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1771040B (zh) * 2003-02-07 2010-06-16 味之素株式会社 糖尿病治疗药
CA2544310A1 (en) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
JPWO2005068467A1 (ja) 2004-01-14 2007-12-27 味の素株式会社 新規縮環化合物
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
NZ563131A (en) 2005-04-28 2010-09-30 Ajinomoto Kk Tricyclic lactam compound as a hypoglycemic agent
EP2157092A4 (en) * 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008136392A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
RU2017126027A (ru) * 2014-12-22 2019-01-24 ЕА Фарма Ко., Лтд. Лекарственное средство для лечения расстройств эпителия роговицы
CA3011538A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
JP7566338B2 (ja) * 2019-01-23 2024-10-15 ▲たん▼解生醫股分有限公司 グルコース代謝障害の長時間作用型の予防または治療に使用するためのβ－ラクタム化合物またはその塩

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
AU8592598A (en) 1997-07-30 1999-02-22 Wyeth Tricyclic vasopressin agonists
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
PL362835A1 (en) * 2000-12-01 2004-11-02 Ajinomoto Co,Inc. Lactam compounds and medicinal use thereof
CN1771040B (zh) * 2003-02-07 2010-06-16 味之素株式会社 糖尿病治疗药

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006213732A (ja) * 2000-12-01 2006-08-17 Ajinomoto Co Inc ラクタム化合物及びその医薬用途

Also Published As

Publication number Publication date
YU42603A (sh) 2006-03-03
US7632830B2 (en) 2009-12-15
KR20030051893A (ko) 2003-06-25
ZA200304100B (en) 2004-08-22
EP1346993A4 (en) 2005-12-21
US7153850B2 (en) 2006-12-26
RU2287530C2 (ru) 2006-11-20
CA2430124A1 (en) 2002-06-06
JP2006213732A (ja) 2006-08-17
NO20032439L (no) 2003-07-18
BR0115852A (pt) 2003-12-23
HUP0400806A3 (en) 2007-11-28
AU2006241377A1 (en) 2006-12-14
BG107857A (bg) 2004-06-30
ES2331299T3 (es) 2009-12-29
DE60140270D1 (de) 2009-12-03
WO2002044180A1 (en) 2002-06-06
NO325401B1 (no) 2008-04-21
HUP0400806A2 (hu) 2004-07-28
JPWO2002044180A1 (ja) 2004-04-02
ATE446297T1 (de) 2009-11-15
EP1346993B1 (en) 2009-10-21
US20080096862A1 (en) 2008-04-24
CN100577651C (zh) 2010-01-06
UA76969C2 (en) 2006-10-16
TWI241302B (en) 2005-10-11
CN1269818C (zh) 2006-08-16
NZ526164A (en) 2004-09-24
US20040048847A1 (en) 2004-03-11
CN1487940A (zh) 2004-04-07
US7326701B2 (en) 2008-02-05
AU2006241377B2 (en) 2009-01-08
IL156158A0 (en) 2003-12-23
JP4505753B2 (ja) 2010-07-21
SK6582003A3 (en) 2003-09-11
PL362835A1 (en) 2004-11-02
MXPA03004876A (es) 2004-01-27
CN1911915A (zh) 2007-02-14
CZ20031520A3 (cs) 2003-10-15
EP1346993A1 (en) 2003-09-24
CA2430124C (en) 2011-01-11
NO20032439D0 (no) 2003-05-28
KR100826818B1 (ko) 2008-05-02
US20060189597A1 (en) 2006-08-24
AU2002218502B2 (en) 2006-09-21
AU1850202A (en) 2002-06-11

Similar Documents

Publication Publication Date Title
JP3826400B2 (ja) ラクタム化合物及びその医薬用途
BG108487A (bg) Заместени с триамид индоли, бензофурани и бензотиофени като инхибитори на микрозомния триглицерид пренасящ протеин (mtp) и/или секрецията на аполипопротеин б (аро в)
WO2005016862A1 (en) Substituted arylalkanoic acid derivative and use thereof
CZ20032696A3 (cs) Thiohydantoiny a jejich použití při léčení cukrovky
WO1999027965A1 (en) Antihyperlipemic agents
JPH01104038A (ja) アラルキルアミノアルコキシフェニル誘導体、その製法およびそれを含有する組成物
TWI331142B (https=)
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
JP2931986B2 (ja) アラルキルアミン誘導体
WO2019105234A1 (zh) 芳香族化合物及其药物组合物和用途
JP2022542613A (ja) ヒトａｔｇｌの阻害剤
DK159435B (da) Analogifremgangsmaade til fremstilling af 2-hydroxy-5-(1-hydroxy-2-piperazinylethyl)benzoesyrederivater eller et farmaceutisk acceptabelt syreadditionssalt deraf
JPWO2005068467A1 (ja) 新規縮環化合物
JP4345097B2 (ja) 縮合多環式化合物およびその医薬用途
CN102234231A (zh) 1-取代-2-取代-4-芳基取代-丁-2-烯1,4-二酮类化合物、其制备方法及其用途
JP2861274B2 (ja) アミノケトン誘導体
JP2961534B1 (ja) 縮合ピリダジン誘導体、その製造法および用途
CN101463019A (zh) 含有芳基、芳甲基和哌嗪基的脒类化合物
CN107304180A (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
JPWO2000055129A1 (ja) ジチオカーボンイミデート誘導体
JPWO1995018092A1 (ja) アミノケトン誘導体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060210

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20060210

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20060306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060625

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 3826400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100714

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100714

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100714

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110714

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110714

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120714

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120714

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120714

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130714

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term